Annex 1 & Microbiological Compliance

Contamination control is where a generalist quality firm runs out of depth fastest.

Annex 1 has been fully applicable since 25 August 2024. Most sterile sites now have a Contamination Control Strategy document. Far fewer have one that survives contact with an investigator asking why a specific intervention, on a specific line, on a specific shift, was judged acceptable.

We work at that level. Environmental monitoring programs designed around the risk actually present in the room rather than a sampling plan inherited from the previous facility. Microbiological investigations that reach a root cause instead of stopping at “operator technique.” Aseptic and sterility failure analysis where the conclusion has to hold up in a 483 response.

This practice sits underneath the rest of the firm. A quality system you can defend and a remediation program you can close both depend on the science being right first.

What We Cover

• Contamination Control Strategy — Annex 1-aligned CCS design, gap assessment against current state, and the written argument that defends it
• Environmental monitoring — program design, risk-based site selection, requalification, and excursion trending that means something
• Microbiological investigations — root cause analysis for bioburden, endotoxin, water system and EM excursions
• Aseptic process simulation — media fill design, failure investigation, and requalification strategy
• Sterility assurance — sterility test failure investigation and sterilization process defense
• Cleanroom qualification and personnel behavior — classification, qualification, gowning and intervention programs
• Rapid microbiological methods — evaluation, comparability and validation strategy

The India Practice

We work with clients in the United States and India. India is where this practice matters most right now. Sterile injectable and aseptic capacity is expanding faster there than anywhere else, a great deal of it at sites qualified before Annex 1 became fully applicable, and a great deal of it supplying US and EU markets under FDA and EU GMP expectations at the same time.

The gap we are usually called into is not equipment. It is the contamination control argument — whether a site can explain, in writing and under questioning, why its controls are adequate for what it makes.

How This Is Usually Scoped

Most contamination control work starts as a Focused Engagement — a single workstream, delivered by the principal. Where Annex 1 findings sit inside a wider regulatory commitment, it runs as part of a Program Engagement governed through the Remediation & Transformation PMO. Either way it begins with a Rapid Diagnostic.